CARDIOLOGY

pic about people

In 2019, the US Food and Drug Administration (FDA) approved the use of EPA-EE for the prevention of cardiovascular events as well as for patients with high blood levels of triglycerides. According to the results of controlled clinical studies, EPA with a daily dose of 2 to 4 grams can reduce the blood level of triglycerides (TG) by 33% and the possibility of cardiovascular events such as heart attack, stroke, the need for cardiac surgery, and Reduce angina by 30%. Also, a study in Japan determined that in a 5-year time horizon, supplemental therapy with EPA along with statin drugs (such as atorvastatin and rosovastatin) can significantly prevent the need for surgical interventions and death from cardiac events. EPA prevents cardiovascular accidents for patients by disrupting the process of atherosclerosis and inhibiting inflammation and deposition of bad cholesterol (LDL). EPA-EE is widely prescribed along with cholesterol-lowering, anticoagulant, and antidiabetic drugs in Europe and America to increase the life expectancy of patients. Several clinical studies show the effects of reducing triglycerides, cholesterol (LDL, VLDL), and Apo B. For more scientific information about the heart protection effects of Epastigel, visit EPALAND.COM.